1/21/2022 10:02:01 AM
Mirati Presents Positive Data With Investigational Adagrasib In Patients With KRASG12C-Mutated Gastrointestinal Cancers
11/22/2021 7:41:07 AM
Mirati, Verastem Partner To Evaluate Adagrasib In Combination With VS-6766 In KRASG12C-Mutant Non-Small Cell Lung Cancer
11/17/2021 7:33:06 AM
Mirati Therapeutics Submits INDA To U.S. FDA Of MRTX1719 To Treat MTAP-Deleted Cancers
11/10/2021 10:08:11 PM
Mirati Therapeutics Prices Underwritten Public Offering Of 3.45 Mln Shares At $145.00/shr
9/20/2021 8:25:32 AM
Mirati Therapeutics Announces Long-term Survival Results From Exploratory Analysis Of Sitravatinib Plus Nivolumab
9/20/2021 8:04:41 AM
Mirati Therapeutics Appoints David Meek As CEO
9/20/2021 7:32:23 AM
Mirati Therapeutics Announces Positive Topline Results From Phase 2 KRYSTAL-1 Study Evaluating Adagrasib